An evaluation of managing and educating patients on the risk of glucocorticoid-induced osteoporosis

Value in Health

Volumn 8, Issue 1, 2005, Pages 24-31

  McDonough, Randy P ^a   Doucette, William R ^a   Kumbera, Patty ^b   Klepser, Donald G ^c  

^a UNIVERSITY OF IOWA   (United States)

^b Outcomes Pharmaceutical Health Care   (United States)

^c S518 PHAR ^*

Author keywords

Glucocorticoid; Osteoporosis; Pharmacist; Steroid

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; ESTROGEN; GLUCOCORTICOID; PREDNISOLONE;

ADULT; AGED; ARTICLE; BONE DENSITY; CONTROLLED STUDY; DRUG MONITORING; ESTROGEN THERAPY; FEMALE; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; OSTEOPOROSIS; PATIENT CARE; PATIENT EDUCATION; PATIENT MONITORING; PHARMACY; PRIORITY JOURNAL; RISK FACTOR; SELF CARE; VITAMIN SUPPLEMENTATION;

EID: 14344258963     PISSN: 10983015     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2005.04007.x     Document Type: Article

References (41)

1. Walsh LJ, Wong CA, Pringle M, et al. Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross sectional study. BMJ 1996;313:344-6.
2. Goldstein MF, Fallon JJ, Harning R. Chronic glucocorticoid therapy-induced osteoporosis in patients with obstructive lung diseases. Chest 1999;116:1733-49.
3. Zaqqa D, Jackson RD. Diagnosis and treatment of glucocorticoid-induced osteoporosis. Clev Clin J Med 1999;66:221-30.
4. Lane NE, Lukert B. The science and therapy of glucocorticoid-induced bone loss. Endocrinol Metab Clin North Am 1998;27:465-81.
5. Reid IR, Veale AG, France JT. Glucocorticoid osteoporosis. J Asthma 1994;31:7-18.
6. Ledford D, Apter A, Manon Brenner A, et al. Osteoporosis in the corticosteroid treated patient with asthma. J Allergy Clin Immunol 1998;102:353-62.
7. Manolagas SC, Weinstein RS. New developments in the pathogenesis and treatment of steroid-induced osteoporosis. J Bone Miner Res 1999; 14:1061-6.
8. Cremer J, Struber M, Wagenbreth I, et al. Progression of steroid-associated osteoporosis after heart transplantation. Ann Thorac Surg 1999;67:130-3.
9. McEvoy CE, Ensrud KE, Bender E, et al. Association between corticosteroid use and vertebral fractures in older men with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;157:704-9.
10. Canalis E. Mechanisms of glucocorticoid action in bone: implications to glucocorticoid-induced osteoporosis. J Clin Endocrinol Metab 1996;81:3441-7.
11. Lukert BP, Raisz LG. Glucocorticoid-induced osteoporosis: pathogenesis and management. Ann Intern Med 1990;112:352-64.
12. Gluck OS, Murhpy WA, Hanh BH. Bone loss in adults receiving alternate day glucocorticoid therapy: a comparison with daily therapy. Arthritis Rheum 1981;24:892-8.
13. Ruegsegger P, Medici TC, Anliker M. Corticosteroid-induced one loss: a longitudinal study of alternate day therapy in patients with bronchial asthma using quantitative computed tomography. Eur J Clin Pharmacol 1994;25:615-20.
14. American College of Rheumatology Task Force on Osteoporosis Guidelines. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheum 1996; 39:1791-801.
15. Adachi JD, Olszynski WP, Hanely DA, et al. Corticosteroid-induced osteoporosis. Semin Arthritis Rheum 2000;29:228-51.
16. Eastell R. Management of corticosteroid-induced osteoporosis. J Intern Med 1995;237:439-47.
17. Pal B. How to manage patients on long-term oral corticosteroids: recommendations from available guidelines. Clin Exp Rheumatol 1997;15:341-32.
18. Adler RA, Hochberg MC. Suggested guidelines for evaluation and treatment of glucocorticoid-induced osteoporosis for the department of veteran affairs. Arch Intern Med 2003;163:2619-24.
19. Saag KG, Emkey R, Schnitzer TJ. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med 1998;339:292-9.
20. Eggelmeijer F. Prevention and treatment of glucocorticoid-induced osteoporosis. Pharm World Sci 1998;20:193-7.
21. Ziegler R, Kasperk C. Glucocorticoid-induced osteoporosis: prevention and treatment. Steroids 1998;63:344-8.
22. Adachi JD, Bensen WG, Brown J. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med 1997;337:382-7.
23. Valentine JF, Sninsky CA. Prevention and treatment of osteoporosis in patients with inflammatory bowel disease. Am J Gastroenterol 1999;94:878-83.
24. Werth VP. Glucocorticoid-induced osteoporosis: evaluation, prevention, and treatment. J Clin Rheumatol 1997;3(Suppl.):S69-73.
25. Reid IR, Schooler BA, Stewart AW. Prevention of glucocorticoid-induced osteoporosis. J Bone Miner Res 1990;5:619-23.
26. Aagaard EM, Lin P, Modin GW, et al. Prevention of glucocorticoid-induced osteoporosis: provider practice at an urban county hospital. Am J Med 1999;107:456-60.
27. Peat ID, Healy S, Reid DM, et al. Steroid-induced osteoporosis: an opportunity for prevention? Ann Rheum Dis 1995;54:66-8.
28. Walsh JL, Wong CA, Pringle M, et al. Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross-sectional study. BMJ 1996;313:344-6.
29. Schaefer B, Cone S. Increasing awareness of osteoporosis: a community pharmacy's experience. US Pharm 1998;23:72-85.
30. Isetts BJ. Osteoporosis screening and risk-reduction services provided in community pharmacies. Minn Pharm 1997;23:2-3,7-8,18,26-9.
31. Elliott ME, Meek PD, Kanous NL. Osteoporosis screening by community pharmacists: use of national osteoporosis foundation resources. J Am Pharm Assoc 2002;42:101-10.
32. Adinoff AD, Hollister JR. Steroid-induced fractures and bone loss in patients with asthma. N Engl J Med 1983;309:265-8.
33. Verstraeten A, Dequeker J. Vertebral and peripheral bone mineral content and fracture evidence in postmenopausal patients with rheumatoid arthritis: effect of low dose corticosteroids. Ann Rheum Dis 1986;45:852-7.
34. Dykman TR, Gluck OS, Murphy WA, et al. Evaluation of factors associated with gluococorticoid-induced osteopenia in patients with rheumatic disease. Arthritis Rheum 1985;28:361-8.
35. Michel BA, Block DA, Fries JF. Predictors of fractures in early rheumatoid arthritis. J Rheumatol 1991;18:804-8.
36. Michel BA, Bloch DA, Wolfe F, et al. Fractures in rheumatoid arthritis: an evaluation of associated risk factors. J Rheumatol 1993;20:1666-9.
37. Saag KG, Koehnke R, Caldwell JR, et al. Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events. Am J Med 1994;96:115-23.
38. Manogalas SC. Corticosteroids and fractures: a close encounter of the third cell kind. J Bone Miner Res 2000;15:1001-5.
39. Pearce G, Tabensky DA, Delmas PD, et al. Corticosteroid-induced bone loss in men. J Clin Endocrinol Metab 1998;83:801-6.
40. National Osteoporosis Foundation. Physician's guide to prevention and treatment of osteoporosis. 2003. Available from: http://www.nof.org (Last accessed Jul 14, 2003).
41. Buckley LM, Leib ES, Cartularo KS, et al. Calcium and vitamin D3 supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis. Ann Intern Med 1996;125:961-8.